- Sarepta Therapeutics, Inc. stock price today and history
Please, Signup (Login) to subscribe or trade (demo)
Sarepta Therapeutics, Inc. stock price
Sarepta Therapeutics, Inc. latest news:
Sarepta shoots higher as sales of $300,000-a-year drug exceed expectations
Sarepta Therapeutics Inc. shares shot more than 13% higher in late trading Wednesday after the company reported sales of its $300,000-a-year drug for Duchenne muscular dystrophy were better than expected. Sarepta announced second-quarter revenue of $35 million, easily beating the average analyst forecast of $22.5 million, according to a FactSet survey. The company underwent a nearly decade-long effort to get FDA approval for eteplirsen, the first approved treatment for DMD. Sarepta also increased its forecast for full-year revenue, to a range of $125 million to $130 million from previous guidance of more than $95 million. Sarepta stock rose to about $38.80 in late trading, after closing with a 0.6% gain at $34.08; the stock is up more than 61% in the past year, as the S&P 500 index has gained 13.7%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Sarepta Therapeutics names new CEO
Drugmaker Sarepta Therapeutics Inc. on Wednesday named Douglas Ingram its next chief executive. Ingram, currently the president and CEO at Allergan PLC's Chase Pharmaceutics, will start Sept. 20, Sarepta said. He replaces Edward Kaye, who took over as interim chief executive in 2015. Last year, Sarepta won government approval for its Duchenne muscular dystrophy drug.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
SB Financial Group, Inc.SBFG
SB Financial Group, Inc.SBFGP
SBA Communications CorporationSBAC
Schmitt Industries, Inc.SMIT
Schnitzer Steel Industries, Inc.SCHN
SciClone Pharmaceuticals, Inc.SCLN
Scientific Games CorpSGMS